U.S., July 24 -- ClinicalTrials.gov registry received information related to the study (NCT07080658) titled '[14C] Study to Investigate the Mass Balance and Biotransformation of WPV01 in Healthy Adult Chinese Male Participants' on July 12, 2024.
Brief Summary: This is a single-center, non-randomized, open-label, single-dose, Phase I clinical study to evaluate the mass balance and biotransformation, safety and tolerability of WPV01 in healthy adult chinese male participants following a single oral administration of [14C] WPV01.
Study Start Date: July 23, 2023
Study Type: INTERVENTIONAL
Condition:
COVID-19
Intervention:
DRUG: [14C]-WPV01
Single oral dose of 600 mg [14C]-WPV01
Recruitment Status: COMPLETED
Sponsor: Westlake Pharmaceu...